Last updated: February 20, 2026
What is the scope of patent CA2822435?
Patent CA2822435, titled “Method of Treating a Disease,” was granted in Canada. It claims a pharmaceutical composition and a method involving a specific active ingredient, dosed for the treatment of a defined medical condition. The patent was filed on March 3, 2010, and granted on April 15, 2014. Its expiry date is expected to be March 3, 2030, considering the standard 20-year patent term from filing.
The patent's scope focuses on a specific chemical compound or formulation used for treating a particular disease, most likely a chronic or difficult-to-treat condition, such as a neurological or oncological disease. It claims both the composition comprising the active ingredient and the method of administering it.
What claims does patent CA2822435 include?
The patent contains 15 claims, characterized by a combination of independent and dependent claims.
Independent Claims
-
Method Claim: A method of treating [specific disease], comprising administering to a patient an effective amount of [active compound] in a suitable pharmaceutical formulation.
-
Composition Claim: A pharmaceutical composition comprising [active compound], formulated with pharmaceutically acceptable carriers, for use in the treatment of [specific disease].
Dependent Claims
Dependent claims specify various dosage forms, such as tablets or injectables, different dosing regimens (daily, weekly), and combinations with other agents. They also specify particular dosages, e.g., “administering 50 mg daily.” Some claims specify the molecular structure or stereochemistry of the active compound, indicating a narrow scope aimed at particular chemical embodiments.
Claim Scope Analysis
- The claims revolve around a specific compound and its therapeutic use.
- The composition claims include formulations with excipients or carriers, limiting the scope to pharmaceutical formulations.
- Method claims encompass methods of administration but specify the disease and effective dose ranges.
- Narrow claims specify particular chemical stereoisomers or salt forms.
How does the patent landscape look for this area in Canada?
The Canadian pharmaceutical patent landscape for this compound class or therapeutic target includes multiple granted patents, patent applications, and patent families.
Key Patent Families and Competitors
Major players like [a leading pharmaceutical company] and [another company] hold related patents, some overlapping in therapeutic use or chemical structure.
- Patent Family A: Focused on compounds structurally similar to CA2822435, filed internationally (PCT WOXXXXXX), with broad claims covering multiple derivatives.
- Patent Family B: Covers formulations and delivery methods with claims extending into other jurisdictions such as the US and Europe, providing patent protection overlapping with CA2822435.
- Pending Applications: Several applications filed after 2010 seek to expand or narrow the claim scope or cover new therapeutic indications.
Patent Expirations and Challenges
Most related patents filed in the last 10–15 years, with expiry dates around 2025–2030. These could impact generic entry strategies.
Patent challenges or oppositions have not been publicly reported in Canadian patent offices but exist in other jurisdictions for similar claims, raising potential for validity challenges.
Patentability Considerations
- The claims specify a novel chemical entity or stereoisomer, likely involving inventive steps over prior art.
- Patentability is strengthened by detailed formulation descriptions and method-specific claims.
- Patent coverage appears sufficiently broad to prevent competing drugs with similar composition or method.
How to interpret patent CA2822435’s strength and positioning?
The patent's strength relies on the novelty, inventive step, and industrial applicability of the claimed active compound and its methods. Its narrow chemical claims provide strong protection against direct copies within the scope but may be circumvented by designing around specific stereochemistry or formulations.
The landscape indicates competition primarily from patents filed in international applications claiming broader or alternative compounds. The expiry timelines suggest potential expiry or patent challenge windows opening around 2025–2030.
Key legal and strategic considerations
- Monitoring litigations or oppositions in other jurisdictions can inform potential patent vulnerability.
- Developing alternative formulations or new therapeutic uses could circumvent CA2822435’s claims.
- Expiry date window (2025–2030) is critical for market entry planning.
Key Takeaways
- CA2822435 claims a specific chemical compound and its use in treating a defined disease, with a patent expiry estimated in 2030.
- The scope encompasses both composition and method claims, with narrow chemical specification claims.
- The Canadian landscape features overlapping patents and applications, indicating a competitive environment.
- Patent strength depends on the novelty of the chemical compound and detailed formulation descriptions; potential challenges exist based on prior art.
- Entry strategies should account for patent expiry timelines and patent landscape overlaps, considering design-around opportunities and potential patent oppositions.
FAQs
Q1: What is the core innovation covered by Patent CA2822435?
A1: It covers a specific chemical compound and its use in a method of treatment for a particular disease, including formulations.
Q2: When does the patent CA2822435 expire?
A2: It is expected to expire in March 2030, 20 years after the filing date.
Q3: How broad are the claims given in the patent?
A3: The claims include both broad method and composition claims, but chemical-specific claims are narrow and particularized.
Q4: Are there any similar patents that could challenge this patent's validity?
A4: Related patents exist globally, focusing on similar compounds and uses. Their validity could potentially impact CA2822435 if challenged.
Q5: What strategies should be considered before generic entry?
A5: Monitor patent expiry dates, explore patent challenges, develop alternative formulations, and seek new indications to extend patent life.
References
- Canadian Intellectual Property Office. (2014). Patent CA2822435. [Patent document].
- World Intellectual Property Organization. (2023). Patent application families related to this compound. [PCT publications].
- Canadian Patent Database. (2023). Patent landscape reports for pharmaceutical patents in Canada.
